Initiated
2026-01-06
Truist
RatingBuy
From—
Target$98
From—
LMND Analyst Ratings
Truist initiated Lemonade at Buy ($98) in January. Morgan Stanley upgraded to Equal-Weight ($85) from Underweight in December, removing a key overhang. Consensus is Buy at $164 average target — improving loss ratios and growth re-acceleration shifting the narrative.
ANALYST RATINGS
LMNDBuy$81
Buy$98
Initiated
2026-01-06
Equal-Weight$85
Upgrade
2025-12-16
Overweight$60
Initiated
2025-08-13
Underweight$24
Downgrade
2025-04-08
Equal-Weight$42
Upgrade
2024-11-20
Upgrade
2025-12-16
Morgan Stanley
RatingEqual-Weight
FromUnderweight
Target$85
From—
Initiated
2025-08-13
Cantor Fitzgerald
RatingOverweight
From—
Target$60
From—
Downgrade
2025-04-08
Morgan Stanley
RatingUnderweight
FromEqual-Weight
Target$24
From—
Upgrade
2024-11-20
Morgan Stanley
RatingEqual-Weight
FromUnderweight
Target$42
From$23
Downgrade
2024-11-07
Keefe Bruyette
RatingUnderperform
FromMkt Perform
Target$21
From$18
Initiated
2024-01-10
TD Cowen
RatingMarket Perform
From—
Target$17
From—
Initiated
2023-06-20
Morgan Stanley
RatingUnderweight
From—
Target$14
From—
Initiated
2023-01-20
BMO Capital Markets
RatingUnderperform
From—
Target$10
From—
Initiated
2022-11-17
Keefe Bruyette
RatingMkt Perform
From—
Target$24
From—
Downgrade
2022-07-18
Piper Sandler
RatingNeutral
FromOverweight
Target$20
From$24
Initiated
2021-11-19
Jefferies
RatingUnderperform
From—
Target$49
From—
Initiated
2021-08-17
Wolfe Research
RatingUnderperform
From—
Target$53
From—
Resumed
2021-04-28
Credit Suisse
RatingUnderperform
From—
Target$56
From—
Initiated
2021-03-09
BofA Securities
RatingUnderperform
From—
Target$29
From—
Upgrade
2021-03-08
Oppenheimer
RatingOutperform
FromPerform
Target$110
From—
Initiated
2020-11-02
Piper Sandler
RatingOverweight
From—
Target$63
From—
Initiated
2020-10-15
Credit Suisse
RatingUnderperform
From—
Target$56
From—